Navigation Links
MIGENIX Reports Preliminary Celgosivir Viral Kinetics Study
Date:12/3/2007

ir Phase II viral kinetics study, along with data from an extension protocol with patients continuing from a previous Phase II non-responder study, to determine the next steps in the development of celgosivir and providing an update as part of the Company's quarterly news release and conference call on December 13th, 2007; and celgosivir having the potential to be included as part of many combination therapeutic approaches to improve efficacy in anti-HCV therapy.

With respect to the forward-looking statements contained in this news release, we have made numerous assumptions regarding, among other things: our ability to complete the analysis of data from the celgosivir studies to provide an update on December 13, 2007; and the competitiveness of the celgosivir study results to date and future results supporting its potential in the treatment of HCV.

Actual results or events could differ materially from the plans, intentions and expectations expressed or implied in any forward-looking statements, including the underlying assumptions thereto, as a result of numerous risks, uncertainties and other factors including: potential delays; uncertainties related to early stage of technology and product development; uncertainties as to the requirement that a drug be found to be safe and effective after extensive clinical trials and the possibility that the results of such trials, if completed, will not establish the safety or efficacy of our products; and other risks and uncertainties which may not be described herein. Certain of these factors and other factors are described in detail in the Company's Annual Information Form and Annual Report on Form 20-F for and other filings with the Canadian securities regulatory authorities and the U.S. Securities & Exchange Commission.

Forward-looking statements are based on our current expectations and MIGENIX assumes no obligations to update such information to reflect later events or developments.

The
'/>"/>

SOURCE MIGENIX Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine news :

1. New Study Reports High Injury Rates for Hotel Workers, Even Higher Rates for Women and Nonwhites
2. Haemacure Reports Third Quarter 2007 Results
3. First-Ever List of the 5,000 Fastest-Growing Businesses Reports Total Revenue of $194.5 Billion
4. Consumer Reports Analysis: Drugs for Nerve Pain, Fibromyalgia Effective, But Not Always Best
5. MDS Reports Third Quarter 2007 Results
6. Allied Healthcare Reports Strong Fourth Quarter, Flat Net Income for Fiscal 2007 vs. 2006
7. AtriCure Reports First Human Implant of the Cosgrove-Gillinov Left Atrial Appendage Occlusion System
8. NMHC Reports Fourth Quarter and Fiscal Year 2007 Financial Results
9. Blue Cross and Blue Shield of Florida Reports Eighteenth Consecutive Year of Positive Performance
10. ReBuilder Medical Technologies, Inc. Reports International Sales Expansion
11. AdCare Health Systems, Inc. Reports Discontinuation of Definitive Merger Agreement with Family Home Health Services, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... (PRWEB) September 18, 2014 Memorial ... made history this week by performing the first ever, ... UNOS (United Network for Organ Sharing) approval to launch ... one of only two programs in South Florida. ... Dr. Enrique Gongora, Medical Director of the ...
(Date:9/18/2014)... -- Older people become more physically vulnerable during bereavement, ... stress hormones during bereavement changes with age, British researchers ... are more likely to have weakened immune systems and ... weeks and months after loss, we can suffer from ... of white blood cell and as such are essential ...
(Date:9/18/2014)... One of the most capable and ... ShandsCair Flight Program’s new EC155 B1, will ... at the Air Medical Transport Conference (AMTC), Sept. 22-24, ... into service ShandsCair EC155 and the Vanderbilt University ... AMTC highlight Airbus Helicopters broad, industry leading line-up of ...
(Date:9/18/2014)... -- Daily supplements of selenium or vitamin E don,t ... cataracts among men, a new study indicates. Previous ... help prevent cataracts. To investigate this further, William Christen, ... in Boston, and his colleagues examined data from a ... trial was initially designed to study prevention of prostate ...
(Date:9/18/2014)... Thousands of college and high school ... fundraising impact on 127 member Children’s Miracle Network ... Dance Marathon Day will officially kick off a school ... raised by college and high school students funding vital ... Dance Marathon campus programs help provide medical equipment, treatment ...
Breaking Medicine News(10 mins):Health News:Memorial Cardiac & Vascular Institute Performs First Adult Heart Transplant in Broward County 2Health News:Memorial Cardiac & Vascular Institute Performs First Adult Heart Transplant in Broward County 3Health News:Memorial Cardiac & Vascular Institute Performs First Adult Heart Transplant in Broward County 4Health News:Grief Can Weigh on Immune System in Older Folks, Study Says 2Health News:Airbus Helicopters Inc. Features Industry-leading Models at AMTC 2Health News:Airbus Helicopters Inc. Features Industry-leading Models at AMTC 3Health News:Airbus Helicopters Inc. Features Industry-leading Models at AMTC 4Health News:Vitamin E, Selenium Supplements Don't Seem to Prevent Cataracts 2Health News:250 Campuses Usher in School Year of Saving Kids’ Lives During First-Ever “Dance Marathon Day” on Sept. 25 2
... ... Locally, , ... WA (PRWEB) July 2, 2010 -- Bill the Butcher Inc. opened a neighborhood butcher ... executive officer., , ,Located at 3800 34th Ave West in Seattle,s Magnolia neighborhood, the ...
... patients with Hodgkin lymphoma (HL) and a history of heart ... after completing treatment, according to research published online today in ... Hematology. HL is a form of cancer of arising in ... the disease in 2009, according to the American Cancer Society. ...
... at Karolinska Institutet recommends a new routine for protection ... for feeding directly through the abdominal wall, is surgically ... simpler and cheaper than the one used today. The ... has been clinically tested on over 200 patients at ...
... Register now for ... of women, at the Mariandale Retreat Center -- right outside of NYC, which will be held ... workshops, room and board, is only $350 until July 9, 2010. , ... New York, NY (PRWEB) July 2, 2010 -- Need to get ...
... ... is pleased to announce the Grand Opening of their newly expanded pain treatment center in ... ... are located at 638 West Duarte Road, Suite 18, Arcadia, California 91007. The Los Angeles ...
... ... , ... 1, 2010-- Aromatherapy isn’t new to the field of natural health. Ancient Egyptians were the ... the Romans to modern day, essential oils have been part of a holistic approach to ...
Cached Medicine News:Health News:In Time for July 4th Grilling, Bill the Butcher Opens 5th Butcher Shop 2Health News:Lymphoma patients with cardiovascular disease have increased risk of cardiac hospitalization 2Health News:Simpler and cheaper antibiotic prophylaxis with insertion of nutrition catheter in the stomach 2Health News:Relax, Release and Rejuvenate at Upcoming Women's Retreat 2Health News:Relax, Release and Rejuvenate at Upcoming Women's Retreat 3Health News:Advanced Pain Institute Opens Expanded Los Angeles Area Pain Management Center 2Health News:Certified Organic Aromatherapy Oils Available from Swanson Health Products 2
(Date:9/18/2014)... BURLINGTON, Mass. , Sept. 18, 2014 /PRNewswire/ ... post-launch in the United States ... have prescribed GlaxoSmithKline,s BRAF inhibitor Tafinlar for ... 49 percent who have prescribed GlaxoSmithKline,s MEK inhibitor ... the highest percentage (42 percent and 43 percent, ...
(Date:9/18/2014)... 18, 2014  Iliad Neurosciences, Inc., a company focused ... treating Autism Spectrum Disorders (ASD) announced today that it ... Research Foundation for The State University of New York. ... new biomarker to identify an abnormality in folate transport ... biomarker is expected to be available for research use ...
(Date:9/18/2014)... BURLINGTON, Mass. , Sept. 18, 2014  Decision ... launched anti-vascular endothelial growth factor (VEGF) agent for wet ... and Medicare Advantage plans as Genentech,s Lucentis, which is ... although surveyed managed care organization (MCO) directors do not ... Eylea is slightly more likely than Lucentis to be ...
Breaking Medicine Technology:At One Year Post-Launch, Approximately One Half of Surveyed U.S. Medical Oncologists Have Prescribed Single-Agent Tafinlar and Mekinist to Their Malignant Melanoma Patients 2Iliad Neurosciences, Inc. enters into an Exclusive License Agreement with The Research Foundation for The State University of New York 2Iliad Neurosciences, Inc. enters into an Exclusive License Agreement with The Research Foundation for The State University of New York 3Regeneron's Eylea and Genentech's Lucentis Are Equally Likely to be Covered on Commercial and Medicare Advantage Plans for Wet AMD 2Regeneron's Eylea and Genentech's Lucentis Are Equally Likely to be Covered on Commercial and Medicare Advantage Plans for Wet AMD 3
... An APTT-based kit for the screening of ... specificity of the test for the factor ... sample plasma with an excess of V-DEF ... possible to discriminate between heterozygous and homozygous ...
Inquire...
Inquire...
... remarkable anti-reflux valve is enclosed ... which prevents the valve from ... in sitting or reclining positions. ... and interference free ensuring uninterrupted ...
Medicine Products: